Comparative Pharmacology
Head-to-head clinical analysis: PRECEF versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRECEF versus TAZIDIME.
PRECEF vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-8 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateWarfarin + Ceftazidime
"Warfarin may increase the anticoagulant activities of Ceftazidime."
Clinical Note
moderatePhenprocoumon + Ceftazidime
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal <10%.
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."